Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Close collaboration between A*STAR’s D3 (Drug Discovery and Development) unit and Experimental Therapeutics Centre accelerates the progress of research on drug candidates from the preclinical stage to proof-of-concept studies in humans.
Invenra’s new proprietary platform, which combines cell-free protein expression with extreme miniaturization, enables the direct phenotypic interrogation of large numbers of full-length antibodies and their derivatives, empowering the discovery of next-generation biologics.
With a distinguished history in the medical sciences and engineering, the University of Southampton continues to lead as a partner of choice in immunology and bioengineering.
QIAGEN (Suzhou) Translational Medicine Co. (TMC) Ltd. is the first diagnostic R&D company focused on translational science in China. The company provides complete solutions for precision medicine through translational science.
Already firmly established as one of the preeminent early-stage biomedical clusters and innovation communities in China, BioBAY is poised to become a leading force in diagnostics and related areas.
Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach.
For over 15 years, GENEWIZ has accelerated life science research and discovery by providing researchers with high-quality, cost-effective, time-saving and innovative genomics solutions.
With promising early-phase data in hand, BrainStorm Cell Therapeutics is now putting its stem cell treatment for amyotrophic lateral sclerosis (ALS) through the rigors of phase 2 testing.
Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners with a common drive for excellence who will share the company’s pursuit of innovation.
Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach.
HitGen’s advanced encoded library technology, including its recently released nonexclusive-use OpenDEL and macrocycle libraries, affords exciting opportunities for those involved in early-stage drug discovery around challenging targets.
CHLA is engaging with internal and external partners to develop healthcare solutions that deliver lifelong benefits for conditions that originate in childhood.
Point of care testing (POCT) enables rapid diagnostic tests to be performed while a patient is at a PoC facility, without the need for complex equipment or a wait of hours to days for reports from outside labs.
The Universidad Nacional Autónoma de México’s technology transfer office—Coordinación de Innovación y Desarrollo—provides a one-stop shop for innovation emerging from Mexico.
